Search the Newsreel

Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

PATRIOT NATIONAL BANCORP INC Q2 2026: Revenue $16.42M, Net income $0.14M, EPS $0— 10-Q Summary

PATRIOT NATIONAL BANCORP INC (PNBK) reported improved second-quarter 2026 results, showing increased revenue and a return to net income compared to a loss in the previous year. This positive shift was primarily driven by substantial loan growth and stronger yields from securities. The company …

What's Going On With Cannara Biotech Inc. Stock Friday?

Patriot National Bancorp, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A

Perceptive Advisors and its related entities have filed an updated 13D/A, disclosing a 9.1% beneficial ownership in Nautilus Biotechnology, Inc. (NAUT), totaling 11,634,211 shares. This ownership is primarily held by Perceptive Life Sciences Master Fund, Ltd. and C2 Life Sciences LLC, with Perceptive Advisors …

Marriott Vacations Worldwide (VAC) Earnings Date and Reports 2026 $VAC

Marriott Vacations Worldwide (VAC) reported strong Q2 2026 earnings, beating analyst estimates for both EPS and revenue. The company posted an EPS of $2.31 and revenue of $1.32 billion, exceeding consensus estimates. Looking ahead, VAC's next earnings date is estimated for November 4, 2026, …

Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.3% in SAB Biotherapeutics (SABS). The Master Fund directly holds 6,627,501 shares, representing this percentage based on 90,986,368 shares outstanding as of August 3, 2026. All …

Krystal Biotech, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS) on August 14, 2026. The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $8,306,750, acquired from the public market on September …

Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting

Moleculin Biotech (NASDAQ: MBRX) is holding its 2026 annual shareholder meeting on October 9, 2026, where key proposals include electing directors, ratifying the independent auditor, and approving an amendment to the 2024 Equity Incentive Plan to increase authorized shares. Shareholders will also vote on …

Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G

Caligan Partners LP and David Johnson have filed an amended Schedule 13G, disclosing beneficial ownership of 7,967,207 shares of SAB Biotherapeutics, Inc. (SABS) common stock, representing an 8.8% stake. This ownership is based on 90,986,368 shares outstanding as of August 3, 2026. Both Caligan …

Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing

MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman have filed an amended Schedule 13G, reporting a collective 7.3% ownership stake in Standard BioTools Inc. (LAB). This amounts to 28,813,904 shares of Common Stock, with shared voting and dispositive power among …

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD

Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, …

RIOT Stock Quote Price and Forecast

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake

Point72 entities, including Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a 7.6% beneficial stake in Atara Biotherapeutics (ATRA). This stake, totaling 687,718 shares of common stock, is held by Point72 Associates, LLC, an investment fund managed by …

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants

Vivo funds have disclosed beneficial ownership of 9.99% stakes in SAB Biotherapeutics (SABS) through various entities, including Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund. These stakes comprise common stock, Series B Preferred Stock, and warrants, with built-in blocking provisions ensuring that ownership …

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS)

Commodore Capital and its related entities have disclosed an 8.95 million share beneficial ownership in SAB Biotherapeutics (SABS), representing a 9.9% stake as of June 30, 2026. This position includes common shares, shares convertible from Series B Preferred Stock, and shares from Tranche 1 …

ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing

ARCH venture funds and related entities, along with several individual managers, have reported an updated collective beneficial ownership of 15.3% in Sana Biotechnology (SANA) common stock as of June 30, 2026. This amounts to 45,860,681 shares based on 299,360,637 shares outstanding. Robert Nelsen, a …

Sana Biotechnology | SCHEDULE 13G/A: Others

This article is a Schedule 13G/A filing for Sana Biotechnology. It indicates an amendment to a previous filing, typically related to significant ownership of the company's stock by an institutional investor or beneficial owner. This is a standard regulatory disclosure.

Did Marriott’s New US$1.24 Billion Debt Raise and Q2 Update Just Shift Its (MAR) Investment Narrative?

BIOTREND CEVRE VE ENERJI (BIOEN) Hisse Senedi

Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price

VAC|Marriott Vacations Worldwide Corp|Price:121.938|Chg%:+0.627

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?

Sana Biotechnology (NASDAQ:SANA) shares dropped 5.3% to $3.4750 on Friday, with trading volume significantly below average. Despite the dip, analyst sentiment is mixed but leans positive, with an average target price of $9.50, although one analyst recently downgraded the stock to "Sell." The company …

Die Marriott-International-Aktie steigt nach höherer EPS-Guidance und stabiler Nachfrage

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's Silver Upgrade to read this MT …

Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Shandong Boan Warns of Interim Loss as R&D Spend Surges

Shandong Boan Biotech Sets Board Meeting to Approve 2026 Interim Results and Mull Dividend

Boan Biotechnology Advances First-in-Class CD228 ADC With Positive Early Trial Data

Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside

Sana Biotechnology, Inc.'s average 12-month price target has been reduced slightly from $9.5 to $9.38 by 8 analysts, with individual forecasts ranging from $6 to $16 per share. Despite the cut, the new target still suggests a significant 155% potential upside based on the …

Will Higher EPS Guidance and New Debt Issuance Change Marriott International's (MAR) Narrative?

In early August 2026, Marriott International completed two fixed-income offerings totaling about US$1.24 billion in callable senior unsecured notes, while also reporting mixed second-quarter results with year-on-year revenue and earnings growth but sales coming in below expectations. Despite external pressures, including weaker performance in …

Trinity Biotech (TRIB) adds $7M Perceptive funding and cures Nasdaq bid-price issue

BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7

BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks …

Trinity Biotech secures $7m from Perceptive Advisors By Investing.com

Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …

Trinity Biotech Regains Nasdaq Compliance After 10 Days at $1 or More